Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733673 | 0.92 | TRPV1 (0.67) | TRPV1GRIK1CNR1 | |
| SCHEMBL2734501 | 0.90 | TRPV1 (0.64) | TRPV1GRIK1CNR1KDR | |
| SCHEMBL2734509 | 0.89 | TRPV1 (0.64) | TRPV1GRIK1CNR1 | |
| SCHEMBL208343 | 0.87 | TRPV1 (0.63) | TRPV1CNR1KDR | |
| SCHEMBL4340613 | 0.87 | TRPV1 (0.69) | TRPV1GRIK1 | |
| SCHEMBL2734357 | 0.86 | TRPV1 (0.63) | TRPV1GRIK1CNR1 | |
| SCHEMBL207820 | 0.86 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL2734753 | 0.83 | TRPV1 (0.67) | TRPV1GRIK1CNR1 | |
| SCHEMBL2734524 | 0.83 | TRPV1 (0.57) | TRPV1CNR1 | |
| SCHEMBL4341397 | 0.82 | TRPV1 (0.69) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | claimed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | claimed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | claimed |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2008-11-06 | — | — | US | claimed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | claimed |
| EP-1569896-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-15 | — | — | EP | claimed |
| US-20060128704-A1 | Tetrahydro-naphthalene derivatives | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | claimed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1569896-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-15 | — | — | EP | disclosed |
| US-20060128704-A1 | Tetrahydro-naphthalene derivatives | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | OPRL1, OPRK1, VAT1 | TRPV1 5/4885GRIK1 110/4885CNR1 28/4885 |
| US-20060128704-A1 | Tetrahydro-naphthalene derivatives | HVCN1, HRH1, OPRL1 | TRPV1 12/4885GRIK1 212/4885CNR1 9/4885 |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | TNNC1, CACNA1H, TNNI3 | TRPV1 13/4885GRIK1 105/4885CNR1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.